SynAct Pharma reports Q3 2026 results, secures convertible financing, advances resomelagon Phase 3 plans

SynAct Pharma's Q3 2026 interim report shows a year-over-year decline in quarterly costs and net losses, supported by a new convertible financing facility. Post-hoc analysis of the ADVANCE study data for resomelagon in rheumatoid arthritis provides a clearer foundation for Phase 3 trial design, with FDA feedback anticipated by end of 2026 or early 2027.

Detected & updated continuously · Source: Nebula